DBT Bureau
Pune, 2 Jan 2026
CORONA Remedies reported a steady improvement in quarterly performance during Q2FY26, driven by higher revenues and improved profitability margins compared to the previous quarter.
Q1FY26 vs Q2FY26 Financial Comparison
| Particulars | Q1FY26 | Q2FY26 | Change (%) |
|---|---|---|---|
| Revenue from Operations (₹ Cr.) | 346.5 | 361.13 | +4.22% |
| Profit After Tax (₹ Cr.) | 46.1 | 52.32 | +13.49% |
| EBITDA Margin (%) | 20.72% | 21.7% | +4.73% |
| PAT Margin (%) | 13.33% | 14.5% | +8.78% |
Financial Performance Summary (₹ in Cr.)
| Particulars | Q2FY26 | H1FY26 |
|---|---|---|
| Revenue from Operations | 361.13 | 707.67 |
| Gross Profit | 292.48 | 573.24 |
| EBITDA | 78.47 | 148.25 |
| EBITDA Margin | 21.7% | 20.9% |
| Profit After Tax (PAT) | 52.32 | 98.52 |
| PAT Margin | 14.5% | 13.9% |
Related story for Q1FY26 result data
